The numbers translate into Snapdeal doing around Rs 1,000 crore GMV in the month.
The chief of new realty PE firm Nisus says REITs have been mistimed.
Acquired by Sanofi, WHO had previously delisted its flagship product but approved it again this year.
Effective today, the co-founders are no longer associated with management of the IT giant.
The venture debt firm will invest Rs 5-15 crore in a portfolio firm.
The new plant coming up in Mysore will have a production capacity of 7.5 million bottles a month.
MakeMyTrip's strategy is different from Info Edge, which has gone beyond its verticals in external investments.
He says PE firms need to make a longer term bet to reap rewards from low-cost housing.
Tiger says investors like BPO sector as it’s an underpenetrated large market and offers long-term growth.
The firm is projecting sales of around Rs 2,600 crore this fiscal.
Piramal Fund is signing cheques worth Rs 600-800 crore a month.
Khan is positioning Orios as an entrepreneur-friendly fund which will not take more than 30 days to write the cheque from the day it meets an entrepreneur.
TA Associates-backed Fractal competes with Mu Sigma, among others.
The firm’s focus is on expanding geographically and getting further into specialties, he says.
The chief of the clean energy firm says that the twin PE funding this year would be enough to take the firm to a mature stage.
The chief of the med-tech firm says the market has not grown as expected but will expand exponentially over the next five years.
There are too many Indian PE funds without enough track record, he says.
Budget would need to provide clarity about the prospective nature of taxation, she says.
The finance head of the drugmaker says inorganic growth in the past now contributes a quarter of revenue.
The venture investment arm of Cipla has backed US-based Chase Pharma, Manipal Group-promoted Stempeutics Research besides two biotech companies.